ライブ・バイオセラピューティクスの世界市場

ライブ・バイオセラピューティクスの世界市場は2030年までに2億4,320万米ドルに達する見込み

2024年に1億1,670万米ドルと推定されるライブ・バイオセラピューティクスの世界市場は、2030年には2億4,320万米ドルに達すると予測され、分析期間2024～2030年のCAGRは13.0%で成長すると予測されます。本レポートで分析したセグメントの1つである胃腸障害治療領域は、CAGR 10.6%を記録し、分析期間終了時には1億560万米ドルに達すると予測されます。代謝疾患治療領域セグメントの成長率は、分析期間中CAGR 16.0%と推定されます。

米国市場は3,180万米ドルと推定され、中国はCAGR 17.1％で成長すると予測される

米国のライブ・バイオセラピューティクス市場は、2024年に3,180万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024年から2030年にかけてCAGR 17.1％をたどり、2030年には予測市場規模5,050万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.7%と11.4%と予測されています。欧州では、ドイツがCAGR 10.2%で成長すると予測されています。

世界のライブ・バイオセラピューティクス市場- 主要動向と促進要因まとめ

なぜ生きたバイオ治療製品が疾患管理のパラダイムシフトとして台頭しているのか？

ライブ・バイオセラピューティクス（LBP）は、宿主に対して治療効果を発揮する生きた微生物を含む医薬品として定義され、腸内マイクロバイオームとシステムオンモジュールを標的とすることで、疾病介入の未来を再形成しています。一般に栄養補助食品に分類される従来のプロバイオティクスとは異なり、LBPは、作用機序、投与量パラメーター、規制当局の監視が定義された厳格な医薬品基準の下で開発されています。LBPの登場は、急速に進歩するマイクロバイオーム科学に裏打ちされたもので、炎症性腸疾患や過敏性腸症候群から神経変性疾患、代謝症候群、免疫調節障害に至るまで、腸内細菌の異常と疾患との間に重要な関連性があることが明らかになっています。

LBPの特徴は、その治療意図と精密な製剤化です。これらの生物製剤は、微生物のバランスを回復させたり、特定の代謝物を産生させたり、病原性細菌を抑制したり、宿主の遺伝子発現を調節したりするように設計されています。臨床段階にあるLBPは、消化器疾患、腫瘍、感染症、自己免疫疾患などのアンメット・ニーズをターゲットにしており、従来の低分子治療薬や生物製剤では達成できなかった成果を示しています。微生物の多様性から微生物の機能性への焦点のシフトは、宿主内で高度に特異的な代謝またはシグナル伝達タスクを実行する能力を持つ菌株を選択する、単一またはコンソーシアムベースのLBPの合理的設計を推進しています。

マイクロバイオーム科学と製造の進歩は、どのようにLBPイノベーションを推進しているのか？

LBPの台頭は、ゲノミクス、メタボロミクス、合成生物学の進歩により、研究者が希望する治療機能のために菌株を分離し、特性を明らかにし、操作することを可能にしました。次世代シーケンサー（NGS）とショットガン・メタゲノミクスは、微生物群集の株レベルの解像度を提供し、治療薬候補の同定と投与後の生着追跡を可能にします。このような高解像度のマッピングは、LBPが長期にわたって在来の微生物叢や宿主生物学とどのように相互作用するかを理解する上で極めて重要です。

製造面では、生存率の維持、再現性の確保、規制レベルの品質管理という課題に、独自の発酵技術、凍結保存、嫌気性バイオプロセシングシステムによって対処しています。胃酸や胆汁酸塩から生物を保護し、小腸や結腸での標的放出を確実にするために、高度なカプセル化や送達技術が開発されています。場合によっては、LBPはコロニー形成と治療効果を高めるプレバイオティック基質や安定化剤と共同配合されます。微生物の完全性や一貫性を損なうことなく、臨床グレードのLBPをスケールアップするために、モジュール式バイオ製造プラットフォーム、クローズドループ生産システム、AI主導の最適化アルゴリズムがますます使用されるようになってきています。

商業化を加速させている治療領域と規制モデルは？

ライブ・バイオセラピューティクスの最も先進的なアプリケーションは、現在、消化器系と免疫系の疾患に見られ、腫瘍学、代謝性疾患、皮膚科学、神経学をターゲットとしたパイプラインが増加しています。糞便微生物叢移植（FMT）は、規制上の意味でのLBPではないが、再発性のクロストリジオイデス・ディフィシル感染症の治療において微生物治療薬の力を実証しており、次世代ソリューションとして、より制御され定義されたLBPへの道を開いています。各社は現在、製品の一貫性、安全性、拡張性を確保しながら、FMTの有効性を再現または改善する単一株LBPや定義されたコンソーシアムLBPを開発しています。

LBPの規制状況は進化しているが、ますます支持されるようになっています。米国FDAは、INDの枠組みの下で、菌株同定、力価測定、製造管理に対する期待を概説した、生きたバイオ治療製品専用のガイダンスを発行しました。欧州医薬品庁（EMA）は、LBPを生物学的医薬品に分類しており、集中的な販売承認を必要としています。いくつかの管轄区域では、規制革新局が開発者と協力し、ファストトラック指定、ローリングレビュー、希少疾病用医薬品の優遇措置など、マイクロバイオーム治療薬の適応経路を構築しています。臨床試験のデザインには、マイクロバイオームのエンドポイントやバイオマーカーに基づく層別化が取り入れられつつあり、LBP反応の個別化されたダイナミックな性質を反映しています。

ライブ・バイオセラピューティクス市場の成長と戦略的関心の原動力は？

ライブ・バイオセラピューティクス市場の成長は、医療科学、バイオテクノロジー、投資エコシステムにわたるいくつかの収束傾向に牽引されています。主要な原動力は、マイクロバイオームがヒト生理学のマスターレギュレーターであり、事実上すべての主要疾患カテゴリーに影響を及ぼすという認識が高まっていることです。このようなシステム生物学的な見地から、製薬会社は、特に従来の治療に難渋している疾患において、LBPを従来の治療の補助、あるいは代替となりうるものとして捉えるようになっています。

開発者が初期段階の発見から後期の臨床試験や商業化戦略に移行するにつれ、バイオファーマとの提携、ライセンシング契約、ベンチャーキャピタルからの資金調達がこの分野に流入しています。大手製薬会社はマイクロバイオーム新興企業と提携し、免疫療法を強化したり、治療に関連する毒性を軽減したり、病気の進行を調節したりするLBPを共同開発しています。特に慢性疾患管理におけるマイクロバイオーム制御の費用対効果が支払者システムによって評価され始めるにつれて、LBPに対する償還の見通しは徐々に改善されつつあります。

さらに、学術研究と官民コンソーシアムによってトランスレーショナル・マイクロバイオーム科学が拡大し、より迅速なパイプライン開発と幅広い治療標的が可能となっています。現在進行中の微生物叢プロファイリング、宿主-微生物叢相互作用モデリング、株工学の革新により、ライブ・バイオセラピューティクスは精密医療ツールの主流クラスとなる準備が整っています。これらの動向は、ヘルスケア全体の予防、治療、さらには治癒のパラダイムを再定義する長期的な可能性を秘めた、強固で急速に成熟しつつある市場を指し示しています。

セグメント

治療領域（消化器疾患、代謝疾患、皮膚疾患、その他の治療領域）、投与経路（経口、直腸、その他の投与経路）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の43社）

• 4D Pharma Plc
• Ancilia Biosciences
• AOBiome Therapeutics, Inc.
• Assembly Biosciences, Inc.
• Caelus Health
• Destiny Pharma Plc
• EnteroBiotix Ltd
• Enterome
• Ferring Pharmaceuticals
• Finch Therapeutics Group, Inc.
• MaaT Pharma
• Microbiotica
• OxThera AB
• Pendulum Therapeutics
• Quorum Innovations
• Rebiotix Inc.
• Sanofi S.A.
• Seres Therapeutics, Inc.
• Vedanta Biosciences, Inc.
• YSOPIA Bioscience

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Live Biotherapeutics Market to Reach US$243.2 Million by 2030

The global market for Live Biotherapeutics estimated at US$116.7 Million in the year 2024, is expected to reach US$243.2 Million by 2030, growing at a CAGR of 13.0% over the analysis period 2024-2030. Gastrointestinal Disorders Therapeutic Area, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$105.6 Million by the end of the analysis period. Growth in the Metabolic Disorders Therapeutic Area segment is estimated at 16.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$31.8 Million While China is Forecast to Grow at 17.1% CAGR

The Live Biotherapeutics market in the U.S. is estimated at US$31.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$50.5 Million by the year 2030 trailing a CAGR of 17.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.7% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.2% CAGR.

Global Live Biotherapeutics Market - Key Trends & Drivers Summarized

Why Are Live Biotherapeutic Products Emerging as a Paradigm Shift in Disease Management?

Live biotherapeutics (LBPs), defined as medicinal products containing live microorganisms that exert therapeutic effects on the host, are reshaping the future of disease intervention by targeting the gut microbiome and systemic immune modulation. Unlike traditional probiotics that are generally classified as dietary supplements, LBPs are developed under strict pharmaceutical standards with defined mechanisms of action, dosage parameters, and regulatory oversight. Their emergence is grounded in rapidly advancing microbiome science, which has revealed critical links between gut microbial dysbiosis and diseases ranging from inflammatory bowel disease and irritable bowel syndrome to neurodegenerative disorders, metabolic syndromes, and immune dysregulation.

What sets LBPs apart is their therapeutic intent and precision formulation. These biologics are being engineered to restore microbial balance, produce specific metabolites, inhibit pathogenic bacteria, or modulate host gene expression. Clinical-stage LBPs are targeting unmet needs in gastrointestinal disorders, oncology, infectious diseases, and autoimmune conditions-demonstrating outcomes that conventional small-molecule therapies and biologics have been unable to achieve. The shift in focus from microbial diversity to microbial functionality is driving the rational design of mono- or consortia-based LBPs, where strains are selected for their ability to execute highly specific metabolic or signaling tasks within the host.

How Are Advancements in Microbiome Science and Manufacturing Driving LBP Innovation?

The rise of LBPs has been enabled by advances in genomics, metabolomics, and synthetic biology that allow researchers to isolate, characterize, and manipulate strains for desired therapeutic functions. Next-generation sequencing (NGS) and shotgun metagenomics provide strain-level resolution of microbial communities, enabling identification of therapeutic candidates and tracking of engraftment following administration. This high-resolution mapping is crucial for understanding how LBPs interact with native microbiota and host biology over time.

On the manufacturing side, the challenges of maintaining viability, ensuring reproducibility, and achieving regulatory-grade quality control are being addressed through proprietary fermentation techniques, cryopreservation, and anaerobic bioprocessing systems. Advanced encapsulation and delivery technologies are being developed to ensure targeted release in the small intestine or colon, protecting organisms from gastric acid and bile salts. In some cases, LBPs are co-formulated with prebiotic substrates or stabilizing agents that enhance colonization and therapeutic effect. Modular biomanufacturing platforms, closed-loop production systems, and AI-driven optimization algorithms are being increasingly used to bring clinical-grade LBPs to scale without compromising microbial integrity or consistency.

Which Therapeutic Areas and Regulatory Models Are Accelerating Commercialization?

The most advanced applications of live biotherapeutics are currently found in gastrointestinal and immunological conditions, with a growing pipeline targeting oncology, metabolic disease, dermatology, and neurology. Fecal microbiota transplantation (FMT), although not an LBP in the regulatory sense, has demonstrated the power of microbial therapeutics in treating recurrent Clostridioides difficile infections-paving the way for more controlled and defined LBPs as next-generation solutions. Companies are now developing single-strain and defined consortium LBPs that replicate or improve upon FMT’s efficacy while ensuring product consistency, safety, and scalability.

The regulatory landscape for LBPs is evolving but increasingly supportive. The U.S. FDA has issued guidance specifically for live biotherapeutic products, outlining expectations for strain identification, potency assays, and manufacturing controls under the IND framework. The European Medicines Agency (EMA) classifies LBPs as biological medicinal products, requiring centralized marketing authorization. In several jurisdictions, regulatory innovation offices are working with developers to create adaptive pathways for microbiome therapeutics, including fast-track designations, rolling reviews, and orphan drug incentives. Clinical trial designs are incorporating microbiome endpoints and biomarker-based stratification, reflecting the personalized and dynamic nature of LBP responses.

What Is Driving Growth and Strategic Interest in the Live Biotherapeutics Market?

The growth in the live biotherapeutics market is driven by several converging trends across medical science, biotechnology, and investment ecosystems. A major driver is the growing recognition of the microbiome as a master regulator of human physiology, with implications across virtually all major disease categories. This systems biology perspective is encouraging pharma companies to view LBPs as potential adjuncts or even alternatives to traditional therapies, particularly in conditions that are refractory to conventional treatment.

Biopharma partnerships, licensing deals, and venture capital funding are flowing into the space as developers move beyond early-stage discovery into late-phase clinical trials and commercialization strategies. Major pharmaceutical companies are forming alliances with microbiome startups to co-develop LBPs that enhance immunotherapy, reduce treatment-related toxicities, or modulate disease progression. As payer systems begin to appreciate the cost-effectiveness of microbiome modulation-especially in chronic disease management-the reimbursement outlook for LBPs is gradually improving.

Additionally, academic research and public-private consortia are expanding translational microbiome science, enabling faster pipeline development and broader therapeutic targeting. With ongoing innovations in microbiota profiling, host-microbiome interaction modeling, and strain engineering, live biotherapeutics are poised to become a mainstream class of precision medicine tools. These trends point toward a robust and rapidly maturing market, with long-term potential to redefine preventive, therapeutic, and even curative paradigms across healthcare.

SCOPE OF STUDY:

The report analyzes the Live Biotherapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutic Area (Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases, Other Therapeutic Areas); Administration Route (Oral, Rectal, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• 4D Pharma Plc
• Ancilia Biosciences
• AOBiome Therapeutics, Inc.
• Assembly Biosciences, Inc.
• Caelus Health
• Destiny Pharma Plc
• EnteroBiotix Ltd
• Enterome
• Ferring Pharmaceuticals
• Finch Therapeutics Group, Inc.
• MaaT Pharma
• Microbiotica
• OxThera AB
• Pendulum Therapeutics
• Quorum Innovations
• Rebiotix Inc.
• Sanofi S.A.
• Seres Therapeutics, Inc.
• Vedanta Biosciences, Inc.
• YSOPIA Bioscience

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Live Biotherapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Interest in Microbiome Therapeutics Throws the Spotlight on Live Biotherapeutic Products
  • Expansion of Gut-Brain Axis Research Propels Growth in Neurological Applications of Live Biotherapeutics
  • Increased Focus on Personalized Microbiome Modulation Strengthens Business Case for Precision LBP Therapies
  • Regulatory Clarifications by FDA and EMA Accelerate Clinical Development and Commercialization
  • Surge in Fecal Microbiota Transplant (FMT) Research Generates Demand for Next-Generation LBPs
  • Growing Pipeline of LBPs for Inflammatory Bowel Diseases Spurs Demand in Gastrointestinal Markets
  • Rising Investment in Synthetic Biology Enhances Engineering of Targeted Probiotic Strains
  • Emerging Use of LBPs in Oncology and Immunotherapy Expands Addressable Market Opportunities
  • Collaborations Between Biotech Firms and Academic Consortia Accelerate Early-Stage Discovery
  • Growth in Companion Diagnostics and Biomarker Integration Drives Personalized Delivery Models
  • Expansion of Contract Manufacturing Capabilities Supports GMP-Compliant LBP Production
  • Rising Prevalence of Antibiotic-Resistant Infections Fuels Demand for Non-Antibiotic Therapies
  • Adoption of Freeze-Drying and Microencapsulation Technologies Enhances Stability and Delivery
  • Increased Public Awareness of Microbiome Health Sustains Consumer Interest in Live Therapeutics
  • Convergence of AI and Microbiome Data Analytics Propels Discovery of Novel LBP Candidates
  • Evolving Guidelines on Microbiome Clinical Trial Design Streamline Regulatory Pathways
  • Growth in Pediatric and Geriatric Gut Health Applications Generates New Product Categories
  • Cross-Species LBP Development for Companion Animals Creates Veterinary Market Potential
  • Supply Chain Constraints in Cultivation and Preservation of Live Cultures Challenge Scalability
  • Rising Focus on Oral and Targeted Colon Delivery Systems Drives Formulation Innovation
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Live Biotherapeutics Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Live Biotherapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Live Biotherapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Live Biotherapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Gastrointestinal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Dermatological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Dermatological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Dermatological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Rectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Rectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Rectal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• JAPAN
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• CHINA
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• EUROPE
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Live Biotherapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Live Biotherapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Live Biotherapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• FRANCE
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• GERMANY
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Live Biotherapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Live Biotherapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Live Biotherapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• INDIA
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Live Biotherapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Live Biotherapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Live Biotherapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Live Biotherapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Live Biotherapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Live Biotherapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030
• AFRICA
  • Live Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Live Biotherapeutics by Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Live Biotherapeutics by Therapeutic Area - Percentage Breakdown of Value Sales for Gastrointestinal Disorders, Metabolic Disorders, Dermatological Diseases and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Live Biotherapeutics by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Live Biotherapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Live Biotherapeutics by Administration Route - Oral, Rectal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Live Biotherapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Rectal and Other Administration Routes for the Years 2015, 2025 & 2030

IV. COMPETITION